Spinal muscular atrophy (SMA) is a genetic disease that destroys the nerve cells controlling voluntary muscle movement, leading to progressive muscle weakness and wasting. It affects roughly 1 in 6,000 to 10,000 live births, making it one of the leading inherited causes of infant death. SMA ranges from a severe form that appears before birth to a mild adult-onset version, and three FDA-approved treatments have dramatically changed outcomes since 2016.
How SMA Damages Motor Neurons
SMA is caused by a mutation in a gene called SMN1, which produces a protein essential for the survival of motor neurons in the spinal cord. Motor neurons are the nerve cells that send signals from your brain and spinal cord to your muscles, telling them to contract. Without enough of this protein, those neurons gradually break down and die. As they disappear, the muscles they once controlled weaken and shrink.
What makes SMA unusual is that the SMN protein is used by every cell in the body, yet only motor neurons seem to be vulnerable when levels drop. Researchers believe low protein levels trigger stress signals inside the cell that activate pathways leading to neurodegeneration. Two of these pathways involve chain reactions of enzymes that, once switched on, disrupt the internal skeleton of the neuron and push it toward self-destruction. The result is a progressive loss of motor neurons that typically hits the muscles closest to the trunk of the body (shoulders, hips, thighs) hardest and earliest.
The Role of the SMN2 Backup Gene
Humans carry two versions of the survival motor neuron gene: SMN1 and SMN2. SMN1 is the primary producer of the protein motor neurons need. SMN2 is a nearly identical backup copy, but it has a small difference that causes it to produce a fully functional protein only about 10 to 15% of the time. The rest of its output is a shortened, unstable version that gets broken down quickly.
People with SMA have a nonfunctional or deleted SMN1 gene on both chromosomes, so they rely entirely on SMN2 to produce whatever functional protein they can. The number of SMN2 copies a person carries varies, and this is the single biggest factor determining how severe the disease will be. Someone with just one or two SMN2 copies produces very little working protein and typically develops the most severe form. Someone with four or more copies produces enough to maintain more motor neuron function and experiences milder symptoms, often not appearing until adulthood.
Types of SMA
SMA is classified into five types based on when symptoms first appear and what motor milestones a person reaches.
Type 0 (Congenital)
This rare and most severe form affects a fetus before birth. Parents and doctors may notice decreased fetal movement during pregnancy. At birth, infants have profound weakness and respiratory failure. Babies with type 0 typically have zero SMN2 copies, and survival beyond a few weeks is uncommon.
Type 1 (Severe)
Symptoms appear within the first six months of life. Infants show marked weakness, low muscle tone (often called “floppy baby” syndrome), and difficulty holding up their heads. Tongue fasciculations, which are small involuntary twitches visible on the surface of the tongue, are present in most infants. The muscles between the ribs weaken while the diaphragm stays relatively intact, creating a bell-shaped chest and a distinctive pattern of abdominal breathing. Sucking and swallowing become difficult, leading to poor weight gain and repeated respiratory infections. Without treatment or breathing support, most children with type 1 do not survive past age two.
Type 2 (Intermediate)
Symptoms appear between 6 and 18 months. Children with type 2 can learn to sit independently but never walk on their own. Weakness tends to affect the legs more than the arms. Scoliosis is common as trunk muscles weaken, and respiratory function gradually declines over years. Around 70% of people with type 2 survive to age 25, and some live into their 30s or beyond, particularly with proactive respiratory and nutritional support.
Type 3 (Mild)
Symptoms appear after 18 months. Children with type 3 can stand and often walk independently, at least for a time. The hallmark is progressive lower limb weakness that makes walking, climbing stairs, and getting up from the floor increasingly difficult. Many people eventually need a wheelchair, but type 3 typically does not shorten life expectancy.
Type 4 (Adult-Onset)
This form doesn’t typically appear until after age 21. Muscle weakness progresses slowly, and most people with type 4 remain mobile throughout their lives. They generally carry four or more SMN2 copies, and life expectancy is normal.
Carrier Frequency and Inheritance
SMA follows an autosomal recessive inheritance pattern, meaning a child must inherit a defective SMN1 gene from both parents to develop the disease. Between 2 and 4% of the general population are carriers, which works out to roughly 1 in every 25 to 50 people depending on ethnic background. Carriers have one working copy of SMN1 and one nonfunctional copy, so they produce enough protein to stay healthy and typically have no symptoms.
When two carriers have a child together, there is a 25% chance the child will have SMA, a 50% chance the child will be a carrier, and a 25% chance the child will not carry the mutation at all. Carrier testing is available through a simple blood test and is often offered as part of preconception or prenatal genetic screening.
How SMA Is Diagnosed
A genetic test is the definitive way to confirm SMA. The gold standard method is called MLPA (multiplex ligation-dependent probe amplification), which can detect whether a person is missing both copies of the SMN1 gene and count how many SMN2 copies they have. That SMN2 count is clinically important because it helps predict disease severity and guides treatment decisions. A related technique called quantitative PCR is also widely used, especially in newborn screening programs, because it’s faster and well suited to processing large numbers of samples.
In the United States, newborn screening for SMA was first implemented in 2018 and has now expanded to all 50 states and Washington, D.C. This is a major development because identifying the disease before symptoms appear allows treatment to begin in the pre-symptomatic window, when it is most effective. Newborns treated before symptoms develop are far more likely to achieve head control, independent sitting, standing, and walking, with many reaching these milestones at developmentally appropriate ages.
Treatments That Target the Root Cause
Three disease-modifying therapies are now approved, each working in a slightly different way to increase the amount of functional SMN protein in the body.
The first, approved in 2016, is an injection delivered directly into the spinal fluid. It works by modifying how the SMN2 gene processes its instructions, coaxing it to produce more of the full-length, functional protein. Because the drug doesn’t cross from the bloodstream into the nervous system on its own, it requires repeated spinal injections on a maintenance schedule.
The second, approved in 2019, is a one-time gene replacement therapy given as a single intravenous infusion for children under two years of age. It uses a harmless virus to deliver a working copy of the SMN gene directly into the body’s cells, essentially replacing what the defective SMN1 gene cannot provide.
The third, approved in 2020, is a daily oral liquid medication. Like the spinal injection, it modifies SMN2 gene processing to boost production of functional protein, but it can be taken by mouth at home, making it the most convenient option for long-term use. In clinical trials, infants with type 1 SMA who took this medication achieved the ability to sit without support, and patients with types 2 and 3 showed measurable improvements in motor function scores.
All three therapies work best when started early. The pre-symptomatic window, before motor neurons have been lost, offers the greatest opportunity for benefit. Once motor neurons die, they cannot be regenerated, so treatment is fundamentally about preserving what remains.
Supportive Care and Daily Management
Even with disease-modifying treatments, most people with SMA benefit from ongoing supportive care that addresses breathing, mobility, nutrition, and skeletal health.
Respiratory support is often the most critical piece. Weak chest muscles make it hard to cough effectively, which allows mucus to build up and increases the risk of pneumonia. Airway clearance techniques like postural drainage, vibration therapy, and manual cough assistance (where a therapist applies pressure to the abdomen or chest during a cough) help keep the lungs clear. Some patients use mechanical cough-assist devices or ventilatory support, especially at night.
Nutrition becomes a challenge when swallowing muscles weaken. Children with type 1 often have difficulty feeding orally and may need a feeding tube placed directly into the stomach to ensure adequate calorie and nutrient intake. Even in milder types, maintaining a healthy weight matters because excess weight increases the workload on already weakened muscles, while being underweight reduces stamina and healing capacity.
Scoliosis develops in many people with SMA types 1 through 3, driven by weakness in the muscles that support the spine. Prolonged sitting in improper postures accelerates spinal curvature and pelvic misalignment. Physical therapy, specialized seating systems, and bracing can help manage mild curves. In more severe cases, spinal fusion surgery may be recommended, sometimes paired with targeted exercises before and after the procedure to optimize outcomes.
Physical and occupational therapy play a continuous role, focusing on preserving range of motion, preventing joint contractures, and adapting daily activities to a person’s current abilities. For children, this often means working with adaptive equipment like power wheelchairs, standing frames, and communication devices to maximize independence and participation in school and social life.